PLGA 85:15 | DLG852A
Tin Free
DLG852A is an acid terminated Pharma / Medical Grade linear co-polymer of polycondesed DL-lactic acid and Glycolic acid OR linear co-polymer of ring-opening polymerisation of DL-lactide and Glycolide in an 85:15 molar ratio and with an inherent viscosity between 0.16 – 0.24 dl/g.
It is supplied in the form of white coloured lyophilized powder.
Primarily utilized in parenteral formulations and medical devices. Its applications extend to tissue engineering, nanoparticle formulation, and microsphere formulation, among other diverse uses.
CAS Number:
26780-50-7
Manufacturing Process:
Polycondensation
Molecular Formula:
(C3H4O2)m x (C2H2O2)n
Synonyms:
PLGA, Poly(D,L-lactic-co-glycolic) acid, Acid terminated
Additional information
| Former CAS Number(s) | 107760-14-5, 119652-89-0, 1255770-56-9, 130953-65-0, 31213-75-9, 339986-68-4 |
|---|---|
| EPA Registry Name | The polylactic acid-polyglycolic acid copolymer |
| Applications | Drug delivery formulations |
| Synonym(s) | 1, 4-Dioxane-2, 5-dione copolymer, 5-dione-1-DL-3, 6-dimethyl-1, Glycolide – lactide copolymer, Glycolide-DL-lactide copolymer, Glycolide-DL-lactide polymer, Lactide – glycolide copolymer, Lactomer, Poly(DL-lactide-co-glycolide), Poly(glycolide – lactide), Poly(glycolide-co-lactide), Polyglactin |
| Substance Type | Biodegradable Polymer, Ester terminated, Excipient, Inherent Viscosity : 1.3 – 1.7 dL/g, Lactide : Glycolide 85:15, Nanoparticles, Non-Active pharmaceutical ingredient, PLGA 75:25 |
| Appearance | |
| Solubility | |
| FT NMR (PROTON) | |
| FT IR | |
| Lactide by NMR | |
| Glycolide by NMR | |
| Viscosity (1% in CHCl3) | |
| Residual monomer DL-Lactide | |
| Residual monomer Glycolide | |
| Residual solvent acetone | |
| Residual solvent toluene | |
| Acid number | |
| Heavy metal | |
| Tin | |
| Sulphated Ash | |
| TAMC | |
| TYMC | |
| Bacterial Endotoxins | |
| Self life | |
| End Group | Acid terminated |
| Molecular Weight | 7,000 – 17,000 da |
| Ratio | lactide:glycolide (85:15) |
Related products
-
Product IDDescriptionSDSDetail -
Product IDPLG 75:25 DLLG 3EDescriptionEster terminated, lactide:glycolide (75:25), Mw 24,000 - 38,000 daDetailVIEW
-
Product IDPLGA 75:25 DLLAGA 2EDescriptionTin FreeEster terminated, lactide:glycolide (75:25), Mw 7,000 - 17,000 daDetailVIEW
Peer Reviewed Papers
Enhanced Drug Release of PLGA Nanoparticle Modified with Polymers: Chitosan
Abstract: The biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) is a biomaterial with great potential as a drug delivery carrier and a... Read More
Size Optimization Bromelain Loaded Nanocarriers by Box Behnken Design
ABSTRACT Bromelain (BRN) is an extensive product of investigation, regarded as effective naturally produced anticancer agents. Heterogeneity of tumors amongst... Read More
CENTRAL COMPOSITE FACE-CENTERED DESIGN-BASED FAVIPIRAVIR-LOADED PLGA
ABSTRACT Objective: The objective of this study is to fabricate favipiravir-loaded PLGA nanoparticulate systems that can increase the solubility along... Read More
Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations
Abstract: The key objective of this research work was to develop and evaluate dry powder for inhalation containing lipid polymer... Read More
SURFACE MODIFIED POLYMERIC NANOPARTICLES FOR ENHANCING DRUG DELIVERY OF METHOTREXATE IN THE BRAIN BY BLOCKING EFFLUX TRANSPORTERS
Abstract: The aim of the present study was to develop, optimize, and evaluate methotrexate containing poloxamer 407 coated polymeric nanoparticles... Read More
Human beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for the management of diabetic wounds
Abstract Diabetic wound (DW) is the most devastating complication resulting in significant mortality and morbidity in diabetic patients. The standard... Read More
Formulation and Evaluation of Pralidoxime-PLGA Microspheres as Antidote against Organophosphorus Poisioning
Abstract Objective: The objective of the present work is to formulate and evaluate Pralidoxime chloride (PAM)-controlled release microspheres using poly... Read More
A tailored solution for localized drug delivery in liver cancer treatment
ABSTRACT Adjuvant chemotherapy is highly recommended for liver cancer to enhance survival rates due to its tendency to recur frequently.... Read More
**Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma
Polymeric lipid hybrid nanoparticles (PHLNPs) are core-shell nanoparticle structures made up of polymer cores and lipid shells that have properties similar to both polymeric nanoparticles and liposomes. Methotrexate (MTX) loaded PLHNPs containing tween 80, phosphatidylcholine, poly D,... Read More
**Statistically designed vitamin D3 Encapsulated PLGA **microspheres dispersed in thermoresponsive in-situ gel for nasal delivery
Vitamin D deficiency is a cause of concern across the world. It is a fat-soluble vitamin and exhibits two molecular forms (D2 and D3). The aim of the present study is the development and optimization of vitamin D3 loaded PLGA microspheres by using Box Behnken Design. Additionally, to enhance nasal... Read More